PIK3CA-related overgrowth: silver bullets from the cancer arsenal?

Ralitsa R. Madsen; Robert K. Semple

doi:10.1016/j.molmed.2022.02.009

PIK3CA-related overgrowth: silver bullets from the cancer arsenal?

Research output: Contribution to journal › Comment/debate › peer-review

Abstract / Description of output

Mutations activating growth factor signaling often drive cancer growth. Many also arise in isolation, causing developmental growth disorders. PIK3CA, encoding a catalytic subunit of phosphoinositide 3-kinase, is a cardinal example of this paradigm. Here recent progress in cancer drug repurposing for PIK3CA-driven overgrowth is discussed.

Original language	English
Journal	Trends in Molecular Medicine
DOIs	https://doi.org/10.1016/j.molmed.2022.02.009
Publication status	Published - 8 Mar 2022

Access to Document

10.1016/j.molmed.2022.02.009

Semple1Accepted author manuscript, 53.6 KBLicence: Creative Commons: Attribution-NonCommercial-NoDerivatives (CC BY-NC-ND)

https://linkinghub.elsevier.com/retrieve/pii/S1471491422000508

Causes and Consequences of Pathological Adipose Remodelling
Semple, R.
UK-based charities
1/06/18 → 31/05/23
Project: Research

Cite this

@article{4def8aeba35f4f8187edbd83ba7e51ca,

title = "PIK3CA-related overgrowth: silver bullets from the cancer arsenal?",

abstract = "Mutations activating growth factor signaling often drive cancer growth. Many also arise in isolation, causing developmental growth disorders. PIK3CA, encoding a catalytic subunit of phosphoinositide 3-kinase, is a cardinal example of this paradigm. Here recent progress in cancer drug repurposing for PIK3CA-driven overgrowth is discussed.",

author = "Madsen, {Ralitsa R.} and Semple, {Robert K.}",

note = "Funding Information: R.K.S. and R.R.M. are supported by fellowships from the Wellcome Trust (grants 210752/Z/18/Z and 220464/Z/20/Z ). Funding Information: R.K.S. has received consulting fees from Novartis and is an investigator in the Novartis-sponsored EPIK-P2 Trial. R.K.S. and R.R.M. have both received research funding from the CLOVES Syndrome Community. Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",

year = "2022",

month = mar,

day = "8",

doi = "10.1016/j.molmed.2022.02.009",

language = "English",

journal = "Trends in Molecular Medicine",